285 related articles for article (PubMed ID: 32804353)
21. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
22. Adherence to endocrine therapy including ovarian suppression: A large observational cohort study of US women with early breast cancer.
Reeder-Hayes KE; Mayer SE; Lund JL
Cancer; 2021 Apr; 127(8):1220-1227. PubMed ID: 33508140
[TBL] [Abstract][Full Text] [Related]
23. Association between nociplastic pain and premature endocrine therapy discontinuation in breast cancer patients.
Joyce E; Carr G; Wang S; Brummett CM; Kidwell KM; Henry NL
Breast Cancer Res Treat; 2023 Jan; 197(2):397-404. PubMed ID: 36371776
[TBL] [Abstract][Full Text] [Related]
24. Adherence to adjuvant endocrine therapy in women with breast cancer.
Danilak M; Chambers CR
J Oncol Pharm Pract; 2013 Jun; 19(2):105-10. PubMed ID: 22895656
[TBL] [Abstract][Full Text] [Related]
25. The effects of adjuvant endocrine therapy on bone health in women with breast cancer.
Ramchand SK; Cheung YM; Yeo B; Grossmann M
J Endocrinol; 2019 Jun; 241(3):R111-R124. PubMed ID: 30991355
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant endocrine therapy for postmenopausal women: Type and duration.
Mayer EL; Burstein HJ
Breast; 2015 Nov; 24 Suppl 2():S126-8. PubMed ID: 26279133
[TBL] [Abstract][Full Text] [Related]
27. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
Mouridsen HT
Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
[TBL] [Abstract][Full Text] [Related]
28. Estrogen deprivation effects of endocrine therapy in breast cancer patients: Incidence, management and outcome.
Cucciniello L; Garufi G; Di Rienzo R; Martinelli C; Pavone G; Giuliano M; Arpino G; Montemurro F; Del Mastro L; De Laurentiis M; Puglisi F
Cancer Treat Rev; 2023 Nov; 120():102624. PubMed ID: 37751658
[TBL] [Abstract][Full Text] [Related]
29. Adherence status to Adjuvant Endocrine Therapy in Chinese Women with Early Breast Cancer and its influencing factors: A cross-sectional survey.
Xu H; Jin F; Zhang XJ; Wang DQ; Yu SF; Wang AP
Cancer Med; 2020 Jun; 9(11):3703-3713. PubMed ID: 32237070
[TBL] [Abstract][Full Text] [Related]
30. Adherence to Adjuvant Endocrine Therapy in Christchurch Women with Early Breast Cancer.
Robinson B; Dijkstra B; Davey V; Tomlinson S; Frampton C
Clin Oncol (R Coll Radiol); 2018 Jan; 30(1):e9-e15. PubMed ID: 29103853
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant endocrine therapy for breast cancer.
Rao RD; Cobleigh MA
Oncology (Williston Park); 2012 Jun; 26(6):541-7, 550, 552 passim. PubMed ID: 22870539
[TBL] [Abstract][Full Text] [Related]
32. Determinants of non-adherence to adjuvant endocrine treatment in women with breast cancer: the role of comorbidity.
Wulaningsih W; Garmo H; Ahlgren J; Holmberg L; Folkvaljon Y; Wigertz A; Van Hemelrijck M; Lambe M
Breast Cancer Res Treat; 2018 Nov; 172(1):167-177. PubMed ID: 30030708
[TBL] [Abstract][Full Text] [Related]
33. The influence of endocrine treatments for breast cancer on health-related quality of life.
Buijs C; de Vries EG; Mourits MJ; Willemse PH
Cancer Treat Rev; 2008 Nov; 34(7):640-55. PubMed ID: 18514425
[TBL] [Abstract][Full Text] [Related]
34. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
Punglia RS; Burstein HJ; Winer EP; Weeks JC
J Natl Cancer Inst; 2008 May; 100(9):642-8. PubMed ID: 18445827
[TBL] [Abstract][Full Text] [Related]
35. Clinical consultations and investigations before and after discontinuation of endocrine therapy in women with primary breast cancer.
Lopez D; Kemp-Casey A; Saunders C; Roughead E; Boyle F; Bulsara M; Preen D
Public Health Res Pract; 2017 Jul; 27(3):. PubMed ID: 28765859
[TBL] [Abstract][Full Text] [Related]
36. Adherence rates and correlates in long-term hormonal therapy.
Dunn J; Gotay C
Vitam Horm; 2013; 93():353-75. PubMed ID: 23810015
[TBL] [Abstract][Full Text] [Related]
37. Optimal duration of endocrine therapy with extended aromatase inhibitors for postmenopausal patients with hormone receptor-positive breast cancer: a meta-analysis.
Chen J; Zhang X; Lu Y; Zhang T; Ouyang Z; Sun Q
Breast Cancer; 2021 May; 28(3):630-643. PubMed ID: 33387283
[TBL] [Abstract][Full Text] [Related]
38. Understanding tamoxifen adherence in women with breast cancer: A qualitative study.
Moon Z; Moss-Morris R; Hunter MS; Hughes LD
Br J Health Psychol; 2017 Nov; 22(4):978-997. PubMed ID: 28850763
[TBL] [Abstract][Full Text] [Related]
39. [Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
van Nes JG; Seynaeve C; van de Velde CJ; Nortier JW
Ned Tijdschr Geneeskd; 2006 Dec; 150(52):2863-9. PubMed ID: 17319217
[TBL] [Abstract][Full Text] [Related]
40. Informing women with breast cancer about endocrine therapy: effects on knowledge and adherence.
Heisig SR; Shedden-Mora MC; von Blanckenburg P; Schuricht F; Rief W; Albert US; Nestoriuc Y
Psychooncology; 2015 Feb; 24(2):130-7. PubMed ID: 24953538
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]